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Background: The positive and negative predictive values of specific IgE to penicillins are not well established for
penicillin hypersensitivity. One reason may be that serum IgE levels to penicillin diminish over time. The objective in
this study was to investigate variations in serum half-life (T½) for specific IgE to penicillins (s-IgE) and to evaluate
the outcome of penicillin challenges in patients with previous but not present specific IgE to penicillins.
Methods: Two subgroups were investigated. All included patients had a history of penicillin allergy with reported
symptoms such as urticaria/angioedema or unclassified cutaneous rash. T½ of specific IgE to penicillins was
calculated based on sera from 29 patients with repeated measurements of s-IgE. Twenty-two patients with a previous
positive s-IgE was followed and challenged with penicillin when IgE had become negative.
Results: The T½ for s-IgE varied between the 26 patients with decreasing s-IgE from 1.6 months to 76.4 months and
52% had a T½ of less than a year. The three patients with stable and increasing IgE-values showed T½ approaching
infinity A total of 29 challenges with β-lactams were performed. Four different patterns were seen when evaluating the
clinical reaction to challenge (positive/negative) and post-challenge boost of s-IgE (yes/no). Eight (36.4%) had negative
challenge and negative post-challenge s-IgE, eight (36.4%) negative challenge, but positive post-challenge s-IgE levels.
3 (13.6%) had positive challenge and positive post-challenge s-IgE whereas 3 (13.6%) were challenge positive, but had
negative post-challenge s-IgE.
Conclusion: Specific IgE to penicillins declines over time stressing the importance of a close time relation between
diagnostic work-up and clinical reaction. Reversal of previously positive s-IgE may still be associated with positive
penicillin challenges and/or re-boostering of s-IgE to positivity.
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Correct diagnosis of allergy to penicillin is of great im-
portance, but in contrast to what is found in a patient
with a history of grass pollen allergy, discrepancy between
skin test, measurement of specific IgE and outcome of
challenge is often seen in patients with suspected penicil-
lin allergy. Recommendations to patients based on false-
negative results can lead to severe adverse reactions
whereas false-positive results can lead to administration of* Correspondence: janni.hjortlund@rsyd.dk
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unless otherwise stated.less effective and more expensive drugs. We have previ-
ously demonstrated [1,2] that challenge tests with penicillin
play an important role in the diagnosis of hypersensitivity
reactions to penicillin. Including a 7-day treatment with a
therapeutic dose of penicillin is of special importance be-
cause patients with negative skin test and negative specific
IgE to penicillins, but with a convincing history of penicil-
lin allergy, may be positive in such a prolonged challenge
test with therapeutic dosing for 7 days. International
guidelines (ENDA and ICON) [3-6] only propose a single
dose challenge. The positive and negative predictive values
of serum specific IgE to penicillins (s-IgE) are not well
established [7-9]. One reason may be that s-IgE levels toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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this study was to determine the serum half-life (T½) of
s-IgE. The second aim was to assess the clinical import-
ance of previous IgE sensitization in patients, where s-IgE
(penicillin V and G, ampicillin and amoxicillin) had be-
come negative. To our knowledge a study on penicillin
challenges has never been performed in patients with




In the period September 2003 to October 2013, our
serum bank contains samples from 2791 adult patients
with suspected penicillin allergy, who had performed
measurements of s-IgE to penicillins. Hereof a total of
287 adult patients had a positive s-IgE to one or more
penicillins (benzylpenicillin (pen G), phenoxymethylpe-
nicillin (pen V), ampicillin (AMP), amoxicillin (AX)).
Serum elimination half-life (T½) of s-IgE (pen G, V, AMP, AX)
A total of 29 patients (10 men and 19 women) had 3 or
more measurements of s-IgE over a period of up to
59 months. These were included for determination of
T½ of s-IgE (pen G, V, AMP, AX), Figure 1. The median
level of s-IgE measurements was 3 measurements (range
3 – 15 measurements). There were no demographic dif-
ferences between the patients included and the patients
with less than three IgE-measurements not included.
Further no demographic differences were found between
the patients with positive s-IgE and the patients with
negative s-IgE (p > 0.05). The most frequently reported
symptoms were urticaria and/or angioedema (17 cases,
58.6%), unclassified cutaneous rash (11 cases, 37.9%) and
anaphylaxis (1 case, 3.5%). Pen V was the culprit drugFigure 1 Algorithm for inclusion criteria. 29 patients included for the es
penicillin challenge in patients with previous IgE sensitization to penicillins
included in both the penicillin challenge in patients with previous IgE sens
penicillins. IgE: Immunoglobulin E, T1/2: half-life for specific IgE to penicillin most cases, 21 (72.4%), the remaining reacting to
dicloxacillin (DX) (4 cases, 13.8%), AX (3 cases, 10.3%)
and unknown in one case (3.5%).Penicillin challenge in patients with previous positive
specific IgE to penicillins
The serum bank contained sera from forty-two patients
followed prospectively with repeated measurements of
s-IgE that had reverted to negative test results. Of these
twenty-two (12 men and 10 women) agreed to partici-
pate in the present study. All patients had negative skin
prick test (SPT) and intracutaneous test (ICT) to peni-
cillins prior to penicillin challenge, Figure 1.
The β-lactam eliciting the initial reaction (culprit drug)
was pen V in 15 cases (62.5%), AX in 5 (20.8%) and DX
in 2 (8.3%).
According to the history reactions commencing within
1 h after drug intake were classified as immediate reac-
tions (IR) and occurred in 7 patients. Reactions commen-
cing 1 h or longer after drug intake were classified as
nonimmediate reactions (NIR) and seen in 15 patients.
Twelve of the 22 patients reported urticaria and/or angio-
edema (6 IR, 6 NIR) and 10 patients with unclassified cu-
taneous rash (1 IR, 9 NIR). Sixteen of the 22 patients had
experienced their initial clinical reaction within one year
prior to measurement of the positive s-IgE (thirteen even
within 6 months), two within 1–5 years and 4 more than
five years prior to blood sampling.
All patients showed undetectable levels of s-IgE at the
time of penicillin challenge. The challenge tests were per-
formed according to procedures in our two previous stud-
ies [1,2], with the modifications described in Figure 2a +
2b. At visit 1, a titrated challenge with penicillin was per-
formed by intravenous injection of pen G from 100 IE to
1.000.000 IE in 10-fold increments and 20 min interval,timation of T½ of specific IgE to penicillins. 22 patients included in
. A total of 50 individuals were included, since 3 subjects were
itization to penicillin and in the estimation of T½ of specific IgE to
ins.
ab
Figure 2 Challenge program in the patients with previous positive specific IgE to penicillins. (A) Challenge program within each visit.
(B) Program for measurements of specific IgE to penicillins. In continuation of each challenge, specific IgE measurements were performed and
repeated 4 weeks later. In case of any positive clinical reaction or renewed positive specific IgE, further challenges were terminated. Visit -1: The visit of
the first positive measurement of specific IgE to penicillin. Visit 0: The visit of the first negative measurement of specific IgE to penicillin. Pen G:
Benzylpenicillin, Pen V: Phenoxymethylpenicillin, p.o.7: prolonged oral challenge with penicillin for 7 days, IgE: specific immunoglobulin E to penicillins
(Pen G, Pen V, ampicillin, amoxicillin). All patients had negative specific IgE to penicillin at the time of penicillin challenge (visit 0 and 1).
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pen V 20 min after the last i.v. dose. If negative, the patient
was at visit 2 given the first two doses (80 mg followed by
800 mg 30 min later) of a 7-day course of pen V in the
clinic. If this challenge was negative, the patient continued
with 800 mg t.i.d. at home. If the above challenges with
pen G and V proved negative and if the case history or
previous positive specific IgE pointed to a reaction to a
different β-lactam antibiotic, the patient was subsequently
challenged with the culprit drug (AX, AMP, DX) in a
titrated oral protocol (visit 3). Three doses were adminis-
tered with 30-min. interval (5, 50 and 500 mg). If negative,
the patient was at visit 4 given the first dose of a 7-day
course of culprit drug (500 mg) followed by dosing
(500 mg b.i.d. (AMP, AX)), and (500 mg t.i.d. (DX)) at
home. In case of a positive reaction (positive challenge or
positive s-IgE) further challenges were terminated. Blood
samples for determination of s-IgE were drawn at visit −1,
0, 1, 2, 3, 4 and four weeks after each visit. In case of
renewed positive s-IgE after any of the visits, the investiga-
tion was stopped and the patient was followed with mea-
surement of s-IgE with 3–6 months interval.
The Regional Scientific Ethical Committees for Southern
Denmark has approved the study (approval number
S-20100091). All patients gave written informed con-
sent for the study as well as consenting to storage of
their blood in the serum bank.
Measurement of specific IgE to penicillins (s-IgE)
S-IgE levels to pen G, pen V, AMP, AX and MDM (minor
determinant mix) were measured using ImmunoCAP
(ThermoFisher Scientific, Uppsala, Sweden). A positive
result was defined as a value ≥ 0.35 kU/L. Total IgE levelswere measured in 20 of the 22 patients included in
the penicillin challenge in patients with previous IgE
sensitization to penicillins (ThermoFischer Scientific,
Uppsala, Sweden).
Serum elimination half-life (T½) of s-IgE (pen G, V, AMP, AX)
Determination of the elimination half-life (T½) of s-IgE
was calculated using WinNonlin 6.3 (Pharsight, Mountain
View, CA, USA). T½ was calculated by the following
equation: T½ = ln [2]/k, where k is the positive value of
the terminal slope of the IgE concentration-time curve.
The majority of the patients (n = 20) had experienced their
initial clinical reaction within one year prior to measure-
ment of the positive s-IgE, three within 5 years and 6 more
than five years prior to blood sampling.
Statistics
Data were analyzed for significance using the Fischer’s
exact test. Probability values of < 0.05 were considered
statistically significant. The statistical analyses were
performed with STATA 13, StataCorp, College Station,
Texas, USA.
Results
The study included 51 cases (48 individual patients, where
3 subjects (all men) were included in both the penicillin
challenge in patients with previous IgE sensitization to
penicillin and in the estimation of T½ of s-IgE.
Serum elimination half-life (T½) of s-IgE (pen G, V, AMP, AX)
For estimation of T½ of s-IgE, 29 (19 women + 10 men)
patients with three or more consecutively serum mea-
surements of specific IgE to one or more penicillins were
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inclusion was 4.3 kU/l (1.4-18.5). Figure 3 shows a
scatter-plot of the sequential positive IgE values for all
penicillins, where the values are given as percentage of
the initial value. A total of 189 measurements of s-IgE
were evaluated; 27 initial values of positive specific IgE
to pen V (17 with mono-sensitization), 9 to initial pen
G, 10 to initial AMP (2 with mono-sensitization) and 4
to initial AX. In three cases initial specific IgE to all four
penicillins were positive. In 8 cases, the specific IgE level
was stable over time (up to 55 months). The T½ for s-IgE
between the 26 patients with decreasing s-IgE varied from
1.6 months to 76.4 months. The three patients with stable
and increasing IgE-values showed T½ approaching infin-
ity, Figure 4. T½ was less than 6 months in 32% of the
patients, 52% was less than a year and 84% had a T½ of
less than 3 years.
Penicillin challenge in patients with previous positive
specific IgE to penicillins
Twenty-two patients had a previous positive s-IgE; all
were skin test negative to the four penicillins (data not
shown). The demographic data, results of specific IgE
determination and outcome of their challenge(s) are pre-
sented in Table 1. Six of the 22 patients (no. 1–6) had a
positive reaction during one of the challenges, three after
a single dose (no. 1, 2 and 5), the remaining reacted dur-
ing (no. 4 and 6) or after (no. 3) the 7-day oral challenge.
In 3 of the 6 patients an elevated post-challenge s-IgE
was detected. Sixteen patients (no. 7–22) were negative
in challenges; in eight of these, (no. 7–14), positive
post-challenge s-IgE was observed either after singleFigure 3 Relative changes in serum concentrations of specific IgE to pen
from base line. The level of the patients’ first positive s-IgE measurement is se
the patients’ first positive s-IgE value. All penicillin – specific IgE includes benzydose (n = 3) or 7-day oral (n = 5) challenge. Post-challenge
s-IgE levels showed large individual variation, neither re-
lated to initial s-IgE level nor to positive or negative
outcome of the challenge, Table 1. Eleven patients had
measurable post-challenge s-IgE, (no. 1, 3, 5, 7–9, 10–14);
3 with positive clinical reaction in challenge (2 IR, 1 NIR)
and 8 negative (5 IR, 3 NIR); they were subsequently
followed with repeated blood samples as described in
Materials and Methods. The post-challenge s-IgE levels
declined over time with varying rates, (data not shown).
Five patients are currently IgE negative (no. 1, 3, 5, 9, 11),
six are still positive (no. 7, 8, 10, 12–14), but specific IgE is
declining. The relation between symptoms and signs in
case history and during challenge together with post-
challenge s-IgE is presented in Table 2. Three patients
(no. 7–9) had negative i.v/single dose challenge with peni-
cillin (G and V) but had positive post-challenge s-IgE to
pen V four weeks later and therefore further challenge was
cancelled. In all three subjects pen V was the culprit drug.
Five patients (no. 10–14) showed positive post-challenge
s-IgE four weeks after a negative outcome of 7-day oral
challenge with pen V. In all 5 cases pen V was the culprit
drug and all had initial positive levels of specific IgE to
pen V. In three of the patients (no. 11, 13 and 14), post-
challenge s-IgE to other penicillins developed. Eleven
patients with either another culprit drug than pen G or V
(no. 5, 6 (DX), 16–18, 20, 21 (AX)) or positive specific IgE
to AMP (no. 5, 6, 9, 14, 15, 19) were also challenged with
the culprit drug in case of negative penicillin challenge
and negative post-challenge s-IgE (n = 10, no. 9, 14 not
challenged, Table 1). Of these, only the two patients with
DX as culprit drug (no. 5, 6) were positive in challenge.icillin presented as the change in amount of specific IgE to penicillin
t to 100 % on a log-scale. Time of sampling is presented in months from
lpenicillin, phenoxymethyl penicillin, ampicillin and amoxicillin.
Figure 4 Distribution of the estimated serum half-life (T½) of specific IgE to penicillins. No differences were seen between the four
penicillins. ∞: Symbol of infinity, including the 3 cases with stable and increasing IgE-values over time. Specific IgE to penicillins includes
benzylpenicillin, phenoxymethyl penicillin, ampicillin and amoxicillin.
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single dose nor 7-day oral challenge outcome, Table 3.Discussion
We describe for the first time the outcome of penicillin
challenge in patients with a history of penicillin allergy
and with previous but not present measurable levels of
specific IgE to penicillins. Further, we describe for the
first time variations in serum half-life of specific IgE in
patients, sensitized to a penicillin.Serum elimination half-life (T½) of s-IgE (pen G, V, AMP, AX)
The present study confirms that levels of s-IgE decline
over time with different rates in the single patient, nei-
ther related to initial level nor to positivity of reaction.
Possible underlying mechanisms behind this variable
decay is unknown, but in concordance with previous
studies having shown that specific IgE antibody levels
tend to decrease over time in the absence of new contact
with the hapten [9-12]. A decline in IgE antibody
responses has previously been described for other
allergens such as chlorhexidine [13] and insect venom
[14]. The patients in our study had no known exposure
to a penicillin after the initial reaction.
T½ for s-IgE varied from 1.6 to 76.4 months. In ap-
proximately half of the patients T½ was less than a year.
Our results thus imply, that a considerable number of
penicillin allergic patients will present with a negative
s-IgE depending on the time elapsed since their clinical
reaction had taken place.Penicillin challenge in patients with previous IgE
sensitization to penicillins
A total of 29 challenges with β-lactam antibiotics were
performed in 22 patients with previous positive specific
IgE to penicillin and negative skin tests. Four different
patterns were seen when evaluating the clinical reaction
to challenge (positive/negative) and post-challenge boost
of s-IgE (yes/no). Eight patients had negative clinical
reaction to challenge and negative post-challenge s-IgE,
8 patients had negative challenge, but positive post-
challenge specific IgE levels. Three patients had positive
clinical reaction to challenge and positive post-challenge
s-IgE whereas 3 patients were challenge positive, but
had negative post-challenge s-IgE. The six cases with
positive challenge should be classified as allergic to peni-
cillin and the 8 cases with negative challenge and nega-
tive post-challenge s-IgE should be classified as not
being allergic. It is difficult to decide how the 8 patients
with negative challenge and subsequent positive post-
challenge s-IgE should be classified and they should
probably be considered as still being allergic. The ap-
pearance of s-IgE after the challenge may be interpreted
as a booster reaction. A conclusion can, however, not be
drawn without actually challenging the patients once
again. Patients with negative s-IgE at the time of investi-
gation and a case history of reaction several years prior
to investigation may have been s-IgE positive at the time
of reaction. The 22 patients in the present study would
have been classified as s-IgE negative if investigated in
average 2.7 years after the clinical reaction took place
(range 0–8 years). The frequency of positive outcomes
Table 1 Demographic data and clinical results of the 22 patients with a history of penicillin allergy and with initial positive serum specific IgE to penicillin
Patient data* Primary reaction Initial IgE Iv/single dose challenge Post IgE
(4 w after challenge)
Challenge p.o.7 Post IgE





























1 F 34 35 Penicillin V urt (IR) 53.1 0.9 0 0 0 0 Neg Pos NT NT NT 2.8 0 0 0 \ NT NT NT NT NT NT NT
2 M 65 69 Penicillin V urt (NIR) 248.6 0.4 0 0 0 0 Neg Pos NT NT NT 0 0 0 0 \ NT NT NT NT NT NT NT
3 M 38 38 Penicillin V urt+angio
(NIR)
101.5 0.5 0 0 0 0 Neg Neg NT NT NT 0 0 0 0 Pos NT NT NT 0.4 0 0 0
4 M 18 19 Penicillin V urt (NIR) 54.1 0.4 0 0 0 0 Neg Neg NT NT NT 0 0 0 0 Pos NT NT NT 0 0 0 0
5 M 56 57 Dicloxacillin urt+angio
(IR)
271.7 0.5 0.4 0.8 0 0 NT NT NT NT Pos 0.4 0 0.4 0 \ NT NT NT NT NT NT NT
6 M 77 81 Dicloxacillin rash (NIR) 1773.0 0 0 0.7 0 0 Neg Neg NT NT Neg 0 0 0 0 Neg NT NT Pos 0 0 0 0
7 F 30 34 Penicillin V urt (IR) 4.2 0.9 0.8 0 0 0 Neg Neg NT NT NT 1.2 0.5 0 0 \ NT NT NT NT NT NT NT
8 M 30 33 Penicillin V urt (IR) 26.8 0.4 0 0 0 0 Neg Neg NT NT NT 0.8 0 0 0 \ NT NT NT NT NT NT NT
9 M 51 56 Penicillin V rash (NIR) 580.7 0 0 0.4 0 0 Neg Neg NT NT NT 0.5 0.7 0 0 \ NT NT NT NT NT NT NT
10 M 43 43 Penicillin V rash (IR) 10.2 0.4 0 0 0 0 Neg Neg NT NT NT 0 0 0 0 Neg NT NT NT >100 0 0 0
11 M 58 58 Penicillin V urt (IR) 142.7 0.4 0 0 0 0 Neg Neg NT NT NT 0 0 0 0 Neg NT NT NT 1.5 0.4 0 0
12 F 48 49 Penicillin V urt+angio
(IR)
38.3 0.8 0 0 0 2.3 Neg Neg NT NT NT 0 0 0 0 Neg NT NT NT 3.9 0 0 0
13 M 51 55 Penicillin V rash (NIR) 363.7 0.4 0 0 0 0 Neg Neg NT NT NT NT NT NT NT Neg NT NT NT 4.3 0.4 0.4 0
14 F 46 49 Penicillin V urt+angio
(NIR)
4.3 3.4 1.4 0.5 0 0 Neg Neg NT NT NT 0 0 0 0 Neg NT NT NT 9.8 2.8 2.9 1.3
15 F 34 38 Penicillin V rash (NIR) 491.2 0 0 0.9 0 0 Neg Neg Neg NT NT 0 0 0 0 Neg Neg NT NT 0 0 0 0
16 F 63 67 Amoxicillin rash (NIR) 107.3 0.4 0 0 0 0 Neg Neg NT Neg NT 0 0 0 0 Neg NT Neg NT 0 0 0 0
17 M 60 61 Amoxicillin rash (NIR) 698.1 3.2 0 0 0 0 Neg Neg NT NT NT 0 0 0 0 Neg NT Neg NT 0 0 0 0
18 F 60 67 Amoxicillin urt (NIR) NT 0.5 0 0 0 0 Neg Neg NT Neg NT 0 0 0 0 NT NT Neg NT 0 0 0 0
19 M 52 52 Penicillin V rash (NIR) NT 0 0 0.7 0 0 Neg Neg Neg NT NT NT NT NT NT Neg Neg NT NT NT NT NT NT
20 F 56 61 Amoxicillin rash (NIR) NT 1.1 1.0 0 0 0 Neg Neg NT Neg NT NT NT NT NT Neg NT Neg NT NT NT NT NT
21 F 58 59 Amoxicillin rash (NIR) NT 0.4 0 0 0 0 Neg Neg NT Neg NT NT NT NT NT Neg NT Neg NT NT NT NT NT
22 F 35 43 Penicillin V urt (NIR) 355.8 0.4 0 0 0 0 Neg Neg NT NT NT NT NT NT NT Neg NT NT NT NT NT NT NT
*Patient data are illustrating the patients’ age at the time of respective IgE positive and IgE negative results.
F: female, M: male, urt: urticarial, angio: angioedema, p.o.7: 7-day oral challenge, pos: positive challenge, neg: negative challenge, NT: not tested, MDM: Minor determinant mix for penicillin, \: not tested due to either

















Table 2 Relation between clinical reaction (case history) and reaction at penicillin challenge, eliciting penicillin, challenge
type and post-challenge levels of s-IgE
Type of reaction Type of challenge Post-challenge s-IgE
Patient no. Case history Challenge Positive 4 weeks later
1 Urticaria (IR) Urticaria (IR) Single p.o Pen V Positive
2 Urticaria (NIR) Maculopapular rash (NIR) Single p.o Pen V Negative
3 Urticaria/angioedema (NIR) Urticaria (NIR) P.o.7 Pen V Positive
4 Urticaria (NIR) Urticaria (NIR) P.o.7 Pen V Negative
5 Urticaria/angioedema (IR) Urticaria (IR) P.o.7 DX Positive
6 Urticaria (NIR) Maculopapular rash (NIR) P.o.7 DX Negative
Bold text indicate concordance between type of reactions eliciting primary reaction and challenge. In the three cases of positive post-challenge s-IgE (no. 1, 3, 5)
concordance was found.
In all cases, the culprit drug and the drug eliciting the clinical reaction during challenge were identical (see Table 1).
IR: immediate reaction, NIR: nonimmediate reaction, s-IgE: serum specific IgE to penicillin, p.o.7: 7-day oral challenge, p.o: per oral, Pen V: phenoxymethylpenicillin,
DX: dicloxacillin.
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lenges – 20.7%) was similar to the findings in our pre-
vious study [2], where all patients challenged had a
positive history but negative specific IgE to penicillin.
Out of 291 challenges 50 had a positive reaction (17.2%)
despite that the patients in the present study had previ-
ous IgE sensitization.
Positive and negative predictive value of serum specific IgE
in patients with a history of penicillin allergy and negative
skin tests
Several studies have evaluated [7,15-20] the positive and
negative predictive value of s-IgE in patients with a posi-
tive history of penicillin allergy but negative skin tests by
performing oral/i.v. challenge test. Silva et al. [7] found
that only 2 of 7 patients with positive s-IgE had a posi-
tive reaction to a challenge test, both were IR with
cutaneous symptoms, indicating that a positive s-IgE in
patients with a history of penicillin hypersensitivity and
negative skin test is not sufficient for confirming the
diagnosis. In the same study 2 of 15 patients with nega-
tive s-IgE had a positive reaction after challenge, giving a
positive predictive value (PPV) of 29% (2/7) and a nega-
tive predictive value (NPV) of 89% (13/15). In another
study Macy et al. [15] challenged four patients withTable 3 Specific IgE level (positive/negative) compared to out
I.v/single p.o (pen V,G) (n = 21)** P.o.7 (p
Pos (n = 2) Neg (n = 19) Pos (n =
Post-challenge
s-IgE
Pos (n = 11) 1 3 1
Neg (n = 25) 1 11* 1
NT (n = 12) 0 5 0
A total of 21 patients were challenged with i.v/single p.o pen V, followed by p.o.7 p
drug (DX).
Nine patients also challenged with other drug (either their culprit drug or because
p.o, and in 1 case* (no. 17, Table 1) initiated by challenge with pen G and V (i.v/sing
single p.o AX). No. 17, Table 1 had not performed p.o.7 with pen V.
s-IgE: serum specific IgE to penicillin, I.v: intravenous, Single p.o: single dose oral ch
benzylpenicillin, DX: dicloxacillin, AX: amocxicillin, Pos: positive, Neg: negative, NT: npositive s-IgE (skin test negative), all with negative out-
come. Aberer et al. [16-18] stated that detection of IgE
antibodies to penicillin does prove sensitization, but not
the existence of a clinical allergy. Torres et al. [19] who
studied 40 patients with positive s-IgE and negative skin
test, found however that 24 patients had a positive IR
(immediate reaction) to penicillin during challenge.
Blanca et al. [20] challenged 3 s-IgE positive, skin test
negative patients with a positive reaction in two only.
Both authors describe a high predictive value of a positive
s-IgE indicating that challenging patients with current
s-IgE will increase the possibility of a positive outcome.
This in contrast to our findings, when challenging
presently negative but previously IgE positive patients.
Immediate reactions (IR)/Nonimmediate reactions (NIR)
Measurement of s-IgE is recommended in patients with
a history of an immediate reaction (IR) [3]. Due to the
low predictive value of the patient history, [2] we recom-
mend both IR and NIR to be evaluated using the same
diagnostic work-up. In this study all 7 patients with IR
in case history ended up with positive post-challenge s-
IgE, but this was also the case in 4 of the 15 patients
with NIR in case history (Table 1). Only 2 respective 1 were
challenge positive. S-IgE to penicillin should therefore become of penicillin challenge (positive/negative)
en V) (n = 15)* Single p.o (other) (n = 8)* P.o.7 (other) (n = 8)*
2) Neg (n = 13) Pos (n = 1) Neg (n = 7) Pos (n = 1) Neg (n = 7)
5 1** 0 0 0
4 0 4 1 4*
4 0 3 0 3
en V in 15 patients. **Patient no. 5 (Table 1) was only challenged with culprit
of previous positive specific IgE to AMP or AX). In 8 cases initiated by single
le p.o), followed by challenge with AX (culprit drug) in p.o.7 (not preceded by
allenge, P.o.7: 7-day oral challenge, Pen V: phenoxymethylpenicillin, Pen G:
ot tested.
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also since many patients are unable to give a detailed case
history regarding time interval between dosage and reac-
tion [21,22] and further due to the fact that s-IgE both can
be positive in challenge proven immediate as well as
nonimmediate responders. Ideally, due to the short T½ in
many patients, s-IgE should be measured within 6 months
after a reaction to penicillin occurred.
The significance of positive specific IgE to penicillin
In a study from 2013 Johansson et al. [23] indicated that
false-positive penicillin immunoassays constitute an
unnoticed, but rather common problem. They found
that 26% of patients with a suspected IgE-mediated re-
action to penicillin and a positive ImmunoCAP might
have specific IgE antibodies to the clinically irrelevant
phenylethylamine with a benzyl group (PEA) instead.
This may be an argument for measurement of PEA anti-
bodies and for the confirmation of an allergy by clinical
tests. Three studies [23-25] have stated that very low
levels of allergen s-IgE should be evaluated with caution
when serum level of total IgE is above 500 kU/l and that
the specificity of tests for anti-β-lactam IgE antibodies
declines progressively with increase of total serum IgE.
Total serum IgE values were measured in 18 patients
(Table 1). Only 3 had total IgE values above 500 kU/l
(8 exceeding 150 kU/l). The patient with the highest level
of total serum IgE (1773 kU/l) was challenge positive,
whereas the others were negative, supporting the theory
that elevated level of total IgE may interfere with mea-
surements of specific IgE to penicillins. No significant
difference between the patients with high and normal
total IgE regarding atopy was found (p > 0.05), data not
shown. Kraft et al. [12] have also shown that patients
with acute allergic reactions to penicillin have high levels
of total serum IgE and that it subsequent decreases in
tune with the decline of specific IgE to penicillins.
Conclusion
An IgE response to penicillin is often a transient phe-
nomenon. In this study approximately half of the pa-
tients had a serum half-life of specific IgE to penicillin of
less than a year, suggesting that the majority of patients
with IgE sensitization at the time of reaction have con-
verted to IgE negativity if measured more than a year
after the incident took place. This is supported by the
finding that we found the same frequency of positive
outcomes during penicillin challenge in the present
study compared to our previous study, where all patients
(with a case history of penicillin allergy) challenged
never had had demonstrable IgE to penicillin [2] in con-
trast to the present study where patients had previous
IgE sensitization. Regarding the challenges with penicillin
in patients with a previous but not present positive s-IgE,a negative sIgE was not associated with tolerance in
63.6% of the tested patients and even a tolerated readmi-
nistration of penicillins (also during iatrogenic diagnostic
workup) may lead to boostering of sIgE with unknown
significance, but possibly reoccurrence of penicillin al-
lergy. Further the more indistinct outcomes in the pa-
tients with negative challenge but positive post-challenge
s-IgE, no firm conclusion can be drawn without challen-
ging the patients once again. Our results thus suggest
that a negative outcome of the 7-day oral challenge
should be followed by measurement of specific IgE
4 weeks later, and only if this proved negative, the
patient should be classified as tolerant to penicillin.
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